- Home
- XOMA vs AGEN Comparison
XOMA vs AGEN Comparison
Compare XOMA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMA
- AGEN
- Stock Information
- Founded
- XOMA 1981
- AGEN 1994
- Country
- XOMA United States
- AGEN United States
- Employees
- XOMA N/A
- AGEN N/A
- Industry
- XOMA Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XOMA Health Care
- AGEN Health Care
- Exchange
- XOMA Nasdaq
- AGEN Nasdaq
- Market Cap
- XOMA 330.2M
- AGEN 87.7M
- IPO Year
- XOMA N/A
- AGEN 2000
- Fundamental
- Price
- XOMA $27.64
- AGEN $7.27
- Analyst Decision
- XOMA Strong Buy
- AGEN Buy
- Analyst Count
- XOMA 2
- AGEN 4
- Target Price
- XOMA $69.50
- AGEN $13.00
- AVG Volume (30 Days)
- XOMA 86.1K
- AGEN 1.4M
- Earning Date
- XOMA 08-12-2025
- AGEN 08-07-2025
- Dividend Yield
- XOMA N/A
- AGEN N/A
- EPS Growth
- XOMA N/A
- AGEN N/A
- EPS
- XOMA N/A
- AGEN N/A
- Revenue
- XOMA $42,909,000.00
- AGEN $99,524,000.00
- Revenue This Year
- XOMA $70.91
- AGEN $12.69
- Revenue Next Year
- XOMA $14.00
- AGEN N/A
- P/E Ratio
- XOMA N/A
- AGEN N/A
- Revenue Growth
- XOMA 638.41
- AGEN N/A
- 52 Week Low
- XOMA $18.35
- AGEN $1.38
- 52 Week High
- XOMA $35.00
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- XOMA 59.23
- AGEN 68.42
- Support Level
- XOMA $26.10
- AGEN $4.78
- Resistance Level
- XOMA $28.70
- AGEN $6.20
- Average True Range (ATR)
- XOMA 1.38
- AGEN 0.62
- MACD
- XOMA 0.13
- AGEN 0.10
- Stochastic Oscillator
- XOMA 79.17
- AGEN 98.90
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).